


Cefixime trihydrate

Cat. No.:	HY-B1381A
CAS No.:	125110-14-7
Molecular Formula:	C ₁₆ H ₂₁ N ₅ O ₁₀ S ₂
Molecular Weight:	507.5
Target:	Bacterial; Antibiotic
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Cefixime trihydrate (FR-17027 trihydrate) is an antibiotic and a third generation cephalosporin antibiotic, useful for the treatment of a number of bacterial infections ^{[1][2]} .
IC₅₀ & Target	β-lactam
In Vitro	Cefixime trihydrate shows great antibacterial activity against clinical isolates of <i>Salmonella typhi</i> , with a MIC ₉₀ value of 0.25 μg/mL, and is also active against β-lactamase producing Amoxicillin (HY-B0467A)-resistant strains ^[3] . Cefixime trihydrate is also active against Enterobacteriaceae, such as <i>Haemophilus influenzae</i> , and <i>Neisseria gonorrhoeae</i> ^[6] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Cefixime (0.75-60 mg/kg, oral gavage) trihydrate reduces the bacterial burden in mice challenged with FA1090 (ESC-susceptible strain) ^[4] . Cefixime (50 or 150 mg/kg, oral gavage) trihydrate changes the structure and abundance of the gut microbiota of C57BL/6J mice, specifically, a reduction in the diversities of the microbial community and decreasing to one preponderant Firmicutes phylum ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Microbiol Spectr. 2023 Apr 24;e0069223.
- Biomed Res Int. 2018 Jul 2;2018:3579832.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Matsumoto Y, et al. Antibacterial activity of cefixime against *Salmonella typhi* and applicability of Etest. *J Infect Chemother.* 1999 Sep;5(3):176-179.
- [2]. Connolly KL, et al. Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant *Neisseria gonorrhoeae* Strains

in the Gonorrhea Mouse Model. *Antimicrob Agents Chemother.* 2019 Feb 26;63(3):e01644-18.

[3]. Shi Y, et al. Restoration of cefixime-induced gut microbiota changes by *Lactobacillus* cocktails and fructooligosaccharides in a mouse model. *Microbiol Res.* 2017 Jul;200:14-24.

[4]. Stone JW, et al. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. *J Antimicrob Chemother.* 1989 Feb;23(2):221-8.

[5]. Neu HC, et al. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime. *Pediatr Infect Dis J.* 1987 Oct;6(10):958-62.

[6]. Unemo M, et al. High-level cefixime- and ceftriaxone-resistant *Neisseria gonorrhoeae* in France: novel penA mosaic allele in a successful international clone causes treatment failure. *Antimicrob Agents Chemother.* 2012 Mar;56(3):1273-80.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA